knowledge -WSS

knowledge

author：focus 2025-10-01 12:34:27 - browse：85758

Jamy Ard (left) and Robert Lustig (right) on the 2023 STAT Breakthrough Summit stage -- coverage from STAT — Obesity experts Jamy Ard (left) and Robert Lustig speak at a panel during the 2023 STAT Breakthrough Summit. Sarah Gonzalez for STAT

Amid rising demand for drugs like Wegovy, Ozempic, and Mounjaro that can lead to significant weight loss, some obesity experts are concerned about the drugs’ costs — both to patients’ finances and to their health.

Speaking at a panel on new obesity treatments at the STAT Breakthrough Summit in San Francisco on Thursday, one expert cited a large clinical trial for Wegovy that showed that about 40% of the weight participants lost was lean mass. Side effects like nausea, vomiting, and a possible link to rare cases of pancreatitis also still plague this newest class of drugs, which imitate the effects of a hormone called glucagon-like peptide 1 (GLP) that helps people feel full.

“That’s what starvation does. You lose equal amounts of muscle and fat,” said Robert Lustig, emeritus professor of pediatrics at the University of California, San Francisco. “If you’re a person 60 years old or over and you’re losing muscle, your risk of dying just went up exponentially. So we may be … robbing Peter to pay Paul.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Startling documents reveal new facets of Sacklers' opioid empire

entertainment

WSS

Report cites 'urgent' need to recruit more diverse clinical trial participants

Too many hospitalized Covid

Adam's Biotech Scorecard: Do Sarepta's exon

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Addiction doctors spar with methadone clinics over legislation

Having children helps parents live longer, especially after age 80

Wikipedia

knowledge

hotspot

How one medical school became remarkably diverse

Insmed lung disease drug hits target in key Phase 3 trial

How to save PrEP access — and even expand it

Long Covid research funding gets a major boost from NIH

Malaria cases in Florida and Texas: Here’s what you need to know

Bernie Sanders gets little from pharma CEOs on drug prices

Affirmative action in medical school literally saved lives

Bernie Sanders gets little from pharma CEOs on drug prices

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Congress must protect the remaining independent doctors

Wikipedia

Why Eli Lilly’s earnings didn’t quite live up to the hype

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

AI used to predict Covid

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Report cites 'urgent' need to recruit more diverse clinical trial participants

First Opinion Podcast: What happens when kids become caregivers?

focus

entertainment

explore

knowledge